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Obstetric hemorrhage is the leading cause of maternal
morbidity and mortality worldwide. Uterine atony leading to
postpartum hemorrhage (PPH) is the most common type seen [1].
Other factors include genital tract lacerations, retained placenta,
uterine inversion, and acquired or inherited coagulo-
pathy. The World Health Organization deﬁnes PPH as a blood loss
in excess of 500 mL after delivery; the common sites for blood loss
include the uterus, cervix, vagina, and perineum [2]. Massive PPH
(> 1 L) accounts for > 10% of all maternal deaths and can lead to
permanent morbidity [3]. Therapeutic management strategies
include uterine compression with massage or manual compres-
sion, compression sutures (B-Lynch procedure), increasing intra-
uterine pressure with balloon catheters or gauze packing, and/or
uterotonic agents or intravenous hemostatic agents such as
tranexamic acid (Transamin) and recombinant activated blood
factor VIIa (rfVIIa) [4].
We describe a case of refractory massive PPH. The bleeding
persisted even though vaginal packing and uterine artery emboli-
zation were administered. Disseminated intravascular coagulation
(DIC) then developed, which we successfully corrected with two
injections of rfVIIa. Interventions with rfVIIa in cases of PPH have
been reported in the past decade. The ﬁrst report of the use of rfVIIa
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womenwith refractory PPH unresponsive to conventional therapy;
such treatment could be useful and could help to avoid emergency
hysterectomy [1].
A 32-year-old parturient woman (gravida 1, para 1), delivered
spontaneously at 38 weeks and 4 days' gestation in a local obstetric
clinic. She was transferred to our hospital because of refractory PPH
after vaginal delivery. The blood loss had been recorded at > 2 L in
the clinic. When arriving at the emergency department, her blood
pressure was 112/65 mmHg with a heart rate of 112 beats/min. The
packing gauzes remained in position in the vagina, but active
bleeding persisted. The initial laboratory data revealed a hemo-
globin level of 8.4 g/dL and a platelet count of 70,000/mL. Blood
transfusions with fresh frozen plasma, packed red blood cells, and
platelets were administered immediately. The patient was
admitted to our intensive care unit for close monitoring of vital
signs and critical care. However, the vaginal bleeding persistedwith
blood loss of > 1.5 L. Subsequent blood analysis showed a hemo-
globin level of 6.9 g/dL and a platelet count of 49,000/mL. We
consulted a radiologist to perform Transcatheter arterial embolism
(TAE), but the effect was not obvious evenwhen both distal internal
iliac arteries and uterine arteries were embolized successfully. After
the procedure, the vaginal bleeding persisted with a further blood
loss of approximately 800 mL. We then administered 2000 mg
(40 mg/kg) of rfVIIa (NovoSeven; Novo Nordisk A/S, Bagsvaerd,
Denmark) intravenously and repeated this dose after 30 minutes.
Blood transfusions were administered according to her hemoglobin
level and the amount of bleeding. The bleeding subsided gradually.
Finally, the hemorrhage diminished, and hemostasis was achieved
successfully.
Interventions with rfVIIa in cases of PPH have been reported in
the past decade. After vascular injury, rfVIIa binds to tissue factors
to form a tissue factorerfVIIa complex that initiates the blood
coagulation cascade [6]. However, rfVIIa also has independent ac-
tivity in the absence of tissue factors. It can activate factor X directly
on platelet surfaces if the dose is high enough. This is the so-called
dose-dependent effect [7].y Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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described with stratiﬁcation into low-, intermediate- and high-risk
patients [8]. The overall survival rate in the low-risk group was
about 85% compared with about 18% in the high-risk patients. This
scoring system could help to predict outcome, and obstetric factors
seemed to improve the prognosis. The efﬁcacy of rfVIIa has been
shown from studies of its biophysical mechanism and from a series
of case reports showing response rates to rfVIIa of 88e95% in cases
of hemorrhage in obstetrical and gynecological situations [9e11].
Moreover, the amount of blood products required for treatment
was signiﬁcantly higher before the use of rfVIIa [9]. Thus, rfVIIa
should be administered early in the bleeding episode, particularly
when there is a loss of > 1.5 times the total estimated maternal
blood volume [9]. The data suggest that the more severe the coa-
gulopathy or thrombocytopenia, the better the response to rfVIIa
[12,13]. The optimal timing of administration of rfVIIa is still unclear
in cases of obstetric hemorrhage [14].
Treatment with rfVIIa is commonly at a dose of 90e100 mg/kg.
This plays a role in hemostasis in cases of PPH even when
complicated with DIC [13,15,16]. Thus, rfVIIa can play an important
role in the management of refractory PPH. The adequate dose of
rfVIIa in cases of obstetric hemorrhage is still unknown because of
its off-label use. Doses can be repeated over a 2-hour period at a
range of 1e18 times the initial single dose [14].
Among patients with hemophilia treated with rfVIIa, the minor
adverse effects were fever, headache, nausea/vomiting, and skin
rashes. The major adverse effects were associated with thrombosis
including myocardial ischemic disease, pulmonary embolisms, and
deep venous and peripheral arterial thromboses [17e19]. The
estimated incidence of such effects was < 1% [17]. However, safety
standards for the use of rfVIIa in pregnant woman are yet to be
established.
Even though there are limitations to its safety and use in ob-
stetrics, our case and previous reports indicate the beneﬁts of
intervention with rfVIIa. In the present case, the rfVIIa successfully
reversed DIC and reduced the amount of blood transfusion needed.
rfVIIa increases the possibility of major adverse effects associated
with thrombosis, therefore, we suggest that rfVIIa should be
administered as early as possible before DIC develops if the patient
is without underlying risk of thrombosis. The timing of adminis-
tration of rfVIIa is related to the successful rate of hemostasis. It
would be ineffective if the rfVIIa was used as a “last-ditch” effort.
The current reports suggest using rfVIIa in critical patients with
bleeding tendency is important to achieve hemostasis [20]. How-
ever, the optimal dose and timing of administration requires
further studies.Conﬂicts of interest
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